Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.W | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by Claridgeon Jul 04, 2019 4:51pm
79 Views
Post# 29887784

RE:RE:RE:RE:RE:Incentives to have a 1st cohort (UHN) 3-month data publish

RE:RE:RE:RE:RE:Incentives to have a 1st cohort (UHN) 3-month data publishSkys1 ... USA is USA.  And Hempdoc correctly documented the spreading of grants.

And until a technology is proven and the issues all solved, all gates are open to others.

You also have toi consider private foundations contribution too.  Below, that was in 2016:


Bladder cancer institute awards $500,000 worth of research grants

The Johns Hopkins Greenberg Bladder Cancer Institute awarded a combined $500,000 to 10 bladder cancer projects.

The institute — established in 2014 as a collaborative initiative of Johns Hopkins Kimmel Cancer Center, Brady Urological Institute, and the Bloomberg School of Public Health and School of Medicine — is designed to advance the scientific understanding of bladder cancer and improve its treatment.


This year’s grants fund six new projects and four renewed projects. Recipients are:

lCorinne Joshu, PhD, MPH, assistant professor of epidemiology at Johns Hopkins Bloomberg School of Public Health and assistant professor of oncology at Johns Hopkins Kimmel Cancer Center;

lMargaret Knowles, PhD, professor of experimental cancer research at University of Leeds, United Kingdom;

lAnirudha Singh, PhD, assistant professor of urology at Johns Hopkins University School of Medicine;

lAlexander Baras, MD, PhD, assistant professor of pathology and urology at Johns Hopkins University School of Medicine;

lShawn E. Lupold, PhD, associate professor of urology, oncology, and radiation oncology and molecular radiation sciences at Johns Hopkins University School of Medicine;

lMichael Johnson, MD, instructor of urology at Johns Hopkins University School of Medicine;

lTrinity Bivalacqua, MD, PhD, associate professor of urology, surgery and oncology at Johns Hopkins University School of Medicine and director of urologic oncology at Johns Hopkins Kimmel Cancer Center;

lGeorge Netto, MD, professor of pathology, urology and oncology at Johns Hopkins University School of Medicine;

lPeter O’Donnell, MD, assistant professor of medicine at University of Chicago; and

lArmine Smith, MD, assistant professor of urology at Johns Hopkins University School of Medicine.

Bullboard Posts